| Depomed, Inc. Q1 2010 Earnings Call Transcript Depomed, Inc. (DEPO)Q1 2010 Earnings Call TranscriptApril 29, 2010 5:00 pm ETComplete Story » seekingalpha.com |
Cubist Pharmaceuticals vs. the Hatch-Waxman Act Jason Chew submits: In 2003, Cubist Pharmaceuticals (CBST) was granted approval for its novel antibiotic, Cubicin, for complicated skin and skin structure infections by Gram-positive bacteria, including drug-resistant strains. Over the next couple years, the stock doubled from about $10 to $20. The stock has languished in the $20 trading range for nearly five years now. There have been some pops and drops to be sure, but in general, the stock has barely budged.At the same time, revenues have grown quite nicely, exceeding even management’s expectations. In 2009, sales reached $562 million; it is expected to reach up to $650 million in 2010 and peak at $1 billion. Net income for 2009 was about $80 million and in fact, the company has been profitable since the third quarter of 2006. Cash flow is strong; the company currently has nearly $500 million in cash, with $245 million in debt.Complete Story » seekingalpha.com |
Biogen Tops Estimates, Raises Guidance on Strong Pipeline Zacks.com submits: Biogen Idec Inc. (BIIB) reported second-quarter earnings per share of $1.27, well above the Zacks Consensus Estimate of $1.08 and the year-earlier figure of 73 cents. Excluding the impact of stock-based compensation expense, second quarter 2010 earnings came in at $1.31 per share. Performance was boosted by higher revenues. Revenues increased 11% to $1.2 billion, with Tysabri and Rituxan being the primary growth drivers. Revenue by Major ProductsComplete Story » seekingalpha.com |
BioReference Laboratories, Inc. to Speak at the UBS Global Life Sciences Conference [Business Wire] - ELMWOOD PARK, N.J.----BioReference Laboratories, Inc. announced today that Marc D. Grodman M.D., President and Chief Executive Officer, is scheduled to speak at the 2010 UBS Global Life Sciences Conference on Monday, September 20, 2010, at The Grand Hyatt Hotel located in New York, NY. us.rd.yahoo.com |
No Trials Required for Teva's Latest Biosimilar: FDA Sending Signals? Pharmalot submits: One of the big questions about establishing a regulatory pathway for approving biologics is the extent to which the FDA will require clinical trials to prove a biosimilar is equivalent to the original brand medicine. This is what is called the great unknown. But the FDA may have sent a signal about its thinking with a decision concerning a Teva Pharmaceutical (TEVA) drug. The FDA issued a Complete Response Letter to Teva, which has been seeking approval to sell a version of Amgen’s (AMGN) Neupogen, a med used to treat infections in people with certain types of cancer. In its press release, Teva notes the FDA “does not require additional pre-marketing clinical trials to complete the review” of the application.Complete Story » seekingalpha.com |